title: Systemic therapy in HCC: lessons from brivanib.
authors: Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine at UCLA, USA.
authors: David
authors: D
authors: Bolos
authors: Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine at UCLA, USA. Electronic address: Rfinn@mednet.ucla.edu.
authors: Richard S
authors: RS
authors: Finn
mesh_terms: D000409:Alanine / Q000031:analogs & derivatives*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy*; D019008:Drug Resistance, Neoplasm / Q000187:drug effects*; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy*; D008297:Male; D009536:Niacinamide / Q000031:analogs & derivatives*; D010671:Phenylurea Compounds / Q000009:adverse effects* / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use*; D016879:Salvage Therapy; D014227:Triazines / Q000627:therapeutic use*
chemical_list: D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D014227:Triazines; D009536:Niacinamide; D000409:Alanine
keywords: Angiogenesis; Brivanib; FGFR; Fibroblast Growth Factor; Hepatocellular carcinoma; Sorafenib; VEGFR; Vascular Endothelial Growth Factor Receptor